NEW YORK, Sept. 30, 2022 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Humanigen, Inc. (“Humanigen” or the “Company”) HGEN in the United States District Court for the District of New Jersey on behalf of all individuals and entities that purchased or otherwise acquired Humanigen Securities between May 28, 2021 and July 12, 2022, both dates inclusive (the “Collection Period”).

All investors who own Humanigen, Inc. and any losses incurred are advised to contact the company immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You can get additional information about the promotion or join the case on our website, www.whafh.com.

When you have suffered casualties Humanigen, Inc.you can, at the latest October 25, 2022, request that the court appoint you lead plaintiff in the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor Humanigen, Inc.

PLEASE CLICK HERE TO JOIN THE EVENT

Humanigen is a clinical-stage biopharmaceutical company focused on the prevention and treatment of what is known as immune overreaction “cytokine storm”, a physiological response in which the immune system causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines, the sudden release of which in large quantities can cause multi-system organ failure and death. The company’s lead product candidate is its proprietary antibody lenzilumab, which is being developed, among other things, to treat cytokine storm associated with COVID-19.

Among other studies, Humanigen is evaluating lenzilumab for the treatment of hospitalized COVID-19 patients in the ACTIV-5/BET-B study, which is part of a direct public-private partnership with the National Institutes of Health.

In May 2021, Humanigen filed an application with the U.S. Food and Drug Administration (“FDA”)…